Overview

A Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Including an Assessment of Receptor Occupancy and Food Effect

Status:
Completed

Trial end date:
2020-03-11

Target enrollment:

Participant gender:

Summary

This is a First-in-Human, Randomized, Placebo-controlled, Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects including Receptor Occupancy Measurements after Single Dose of SDI-118 and an Assessment of Food Effect.

Phase:

Phase 1

Details

Lead Sponsor:

AbbVie

Collaborators:

KU Leuven
Syndesi Therapeutics